Keywords
Phosphate binder
Rationality of drug use
How to Cite
Abstract
Introduction: Chronic kidney disease (CKD) is a progressive and irreversible end-stage renal disease or impairment of kidney function. Hyperphosphatemia is an independent predictor of cardiovascular disease and death in patients with advanced chronic kidney disease (stages 4 and 5) and is caused by impaired renal excretion of phosphate. Serum phosphate is usually managed with oral phosphate binders along with dietary phosphate restriction. Method: Descriptive with retrospective data collection using patient medical record data from July 2020 to December 2022 in the medical record room at Private Hospital X Semarang Results: The results of data analysis showed that 30 patients met the inclusion criteria. The results showed the accuracy of the use of phosphate binder drugs in chronic kidney failure patients, namely 100% correct patient, 100% correct indication, 100% correct drug, 100% correct dose in accordance with the literature. Conclusion: The pattern of phosphate binder use at Private Hospital X Semarang is in accordance with the literature
References
Johansen KL, Chertow GM, Foley RN, Gilbertson DT, Herzog CA, Ishani A, et al. US Renal Data System 2020 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2021;77(4):A7–A8. doi:10.1053/j.ajkd.2021.01.002
Al Kamaliah NI, Cahaya N, Rahmah S. Characteristics of Chronic Kidney Failure Patients Using Calcium Supplements at the Kidney and Hypertension Outpatient Clinic at Ulin Regional Hospital, Banjarmasin. J Pharmascience. 2021;8(1):111. doi:10.20527/jps.v8i1.8599
Chan S, Au K, Francis RS, Mudge DW, Johnson DW, Pillans PI. Phosphate binders in patients with chronic kidney disease. Aust Prescr. 2017;40(1):9–14. doi:10.18773/austprescr.2017.002
Hartini S. Characteristics of Chronic Kidney Failure Patients Undergoing Hemodialysis at Dr. Moewardi Regional General Hospital. Nurs J. 2016;2(1):1–15.
Hutchison AJ. Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate. 2008;4(5):887–893.
Nasution SH, Syarif S, Musyabiq S. Chronic Kidney Failure Disease Stage 5 Based on Determinants of Age, Gender, and Diagnosis of Etiology in Indonesia in 2018. JK Unila. 2020;4(2):157–160.
Pernefri. 9th Report of Indonesian Renal Registry. Indonesian Nephrology Association; 2016:1–46.
Prasetya N, Tanty HN, Iskandar H, Pranacistri R. Description of Medicine Use in Chronic Kidney Disease (CKD) Patients on Hemodialysis in X Hospital Bekasi From January to March 2020. Indones Pharm Res J. 2022;4(2).
Sholihah I, Santoso J, Rahardjoputro R. Overview of Phosphate Binder Use in Chronic Kidney Disease Patients with Hemodialysis. 2022;6:91–97.
Sumawa PMR, Wullur AC, Yamlean PVY. Evaluation of the Rationality of Antihypertensive Drug Use in Inpatient Hypertensive Patients at Prof. Dr. RD Kandou Manado General Hospital in January-June 2014. Pharmacon. 2015;4(3):126–133.
Setiani L, Effendi I, Syamsudin A. Influence of the use of phosphate binders on serum levels of calcium phosphate in patients with chronic kidney disease undergoing hemodialysis: A retrospective and prospective study. Saudi Pharm J. 2014;22:333–337.
Mahdiana R. Heart & Kidney Health Combination. In: Heart & Kidney Health Guide. Vol. 5, Issue 4. Citra Medical; 2011:19–30.